Biotech | April 06, 2022
Singlera Genomics announces research collaboration with Astellas Pharma
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Lupin updates on shipment of Mirabegron ER Tablets
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Subscribe To Our Newsletter & Stay Updated
